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Background: Clostridium difficile is the leading cause of antibiotic-associated diarrhoea, both in health-
care facilities and in the community. The recurrence rate of C. difficile infection (CDI) remains high, up to
20%. Since the publication of the European Society of Clinical Microbiology and Infectious Diseases
(ESCMID) guidance document on CDI treatment in 2014, new therapeutic approaches have been
developed and tested to achieve higher sustained clinical cure in CDI.
Aim: To review novel treatments and approaches for CDI, except probiotics and vaccines. We focused on
new antibiotics, antibiotic inactivators, monoclonal antibodies and gut microbiota modulating therapies.
Sources: A literature review was performed for clinical trials published in PubMed, Embase or Cochrane
Library between January 2013 and November 2017.
Content: We analysed 28 clinical trials and identified 14 novel agents. Completed phase 2 studies were
found for cadazolid, LFF571, ridinilazole and nontoxigenic C. difficile strains. Four phase 3 active
comparator studies comparing vancomycin with bezlotoxumab, surotomycin (n ¼ 2) and rifaximin have
been published. Seven clinical trials for treatment of multiple recurrent CDI with faecal microbiota
transplantation were analysed, describing faecal microbiota transplantation by upper or lower gastro-
intestinal route (n ¼ 5) or by capsules (n ¼ 2).
Implications: Metronidazole is mentioned in the ESCMID guideline as first-line therapy, but we propose
that oral vancomycin will become the first choice when antibiotic treatment for CDI is necessary.
Fidaxomicin is a good alternative, especially in patients at risk of relapse. Vancomycin combined with
faecal microbiota transplantation remains the primary therapy for multiple recurrent CDI. We anticipate
that new medication that protects the gut microbiota will be further developed and tested to prevent CDI
during antibiotic therapy. R.E. Ooijevaar, Clin Microbiol Infect 2018;24:452
© 2018 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.of Medical Microbiology and
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Clostridium difficile, recently reclassified as Clostridioides difficile,
is the most common cause of hospital-acquired infectious diar-
rhoea and is strongly associated with antibiotic use [1]. The clinical
symptoms associated with C. difficile infection (CDI) range from
mild, self-limiting diarrhoea to fulminant (pseudomembranous)
colitis and toxic megacolon, leading to bowel perforation, sepsis
and/or multiple organ failure [2]. Approximately 20% of CDI reoc-
curs [3], most likely associated with a persisting dysbiosis of theblished by Elsevier Ltd. All rights reserved.
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antibodies against C. difficile toxins [2]. The main virulence factors
of C. difficile are high-molecular-weight clostridial toxins: toxin A
(TcdA) and toxin B (TcdB) [2]. TcdA and TcdB bind and enter the
colonic epithelium, causing proinflammatory chemokine and
cytokine production, influx of neutrophils, disruption of tight
junctions, fluid secretion and epithelial cell death [2]. Some strains,
including so-called hypervirulent strains (PCR ribotypes 027 and
078), additionally produce a binary toxin, the significance of which
remains to be elucidated [4].
In 2014 Debast et al. [5] published a guideline on CDI treatment,
approved by the European Society of Clinical Microbiology and
Infectious Diseases (ESCMID). Metronidazole, vancomycin and to a
lesser extent fidaxomicin were considered to be the cornerstone of
antibiotic treatment for CDI. The European guidance document
agreedwith guidelines of the Infectious Diseases Society of America
and the American College for Gastroenterology that metronidazole
could be considered as the first agent of choice for mild CDI [5e7],
but novel agents and CDI treatments have been further developed
and studied, including faecal microbiota transplantation (FMT)
[8,9]. Herewe review and discuss novel treatments and approaches
to prevent CDI, except probiotics and vaccines. We focus on new
antibiotics, antibiotic inactivators, monoclonal antibodies and gut
microbiota modulating therapies and discuss their efficacy in
clinical trials.
Definitions by ESCMID
CDI is defined as a clinical picture compatible with CDI such as
diarrhoea, ileus and toxic megacolon in combination with either
microbiologic evidence of free toxins in stool or the presence of
toxigenic C. difficile in stool without reasonable evidence for an
alternative cause of diarrhoea; or pseudomembranous colitis
diagnosed during endoscopy, after colectomy or at autopsy [5].
Recurrent CDI (rCDI) is defined as a recurrence of CDI symptoms
within 8 weeks after the onset of a previous episode, provided the
symptoms from the previous episode resolved after completion ofTable 1
Definitions of severe and complicated CDI
Guideline Severe CDI
European Society of Clinical Microbiology
and Infectious Diseases [5]
Episode of CDI with one or more
symptoms of severe colitis or a c
disease, with significant systemic
resulting in need for ICU admissi
One or more of following unfavo
can be present without evidence
 Marked leucocytosis (leucocy
mm3).
 Decreased blood albumin (<30
 Rise in serum creatinine level
premorbid level).
American College of Gastroenterology [7] Serum albumin <3 g/dL, plus eith
 White blood count 15 000 ce
 Abdominal tenderness.
Infectious Diseases Society of America [6] Leukocytosis (white blood cell co
higher)
OR
Serum creatinine level 1.5 time
CDI, Clostridium difficile infection; ICU, intensive care unit.the initial treatment [5]. This definition does not include specific
clinical and microbiologic criteria.
Severe CDI is defined as an episode of CDI with (one or more
specific signs and symptoms of) severe colitis or a complicated
course of disease, with significant systemic toxin effects and shock,
resulting in need for intensive care unit admission, colectomy or
death [5]. This ESCMID definition differs from definitions of two
other guidelines (Table 1) by incorporating the definition of
complicated CDI into the definition of a severe CDI syndrome [5e7].
Initial cure is defined as no diarrhoea for two consecutive days
after completion of standard-of-care antibiotic therapy. Sustained
(or global) cure is defined as initial clinical cure of the baseline
episode of CDI and no recurrent infection through 12 weeks'
follow-up.
Literature search
A literature search was performed on PubMed, the Cochrane
Library and Embase on 17 July 2017 (Fig. 1). The following MeSH
terms were used: ‘Clostridium difficile,’ ‘therapy,’ ‘therapeutics,’
‘treatment.’ In addition, the following filters were applied: publi-
cation date from 1 January 2013 and clinical trials. The publication
date filter was chosen to identify novel treatment strategies not
reviewed by the ESCMID guideline on CDI treatment [5]. EndNote
X8 software (Clarivate Analytics, Philadelphia, PA, USA) was used to
compile a database. The search led to a final inclusion of 28 clinical
trials identifying 14 novel agents (Table 2).
In addition to these results, various other articles were identified
and included after searching by agent-specific terms, as well as
articles cited in other articles.
Comments on current CDI treatment guideline treatment by
ESCMID
A summary of the treatment guideline from 2014 is shown in
Table 3. Metronidazole was advised as first-line treatment for
nonsevere CDI and vancomycin as the first choice for severe CDI [5].Complicated CDI
specific signs and
omplicated course of
toxin effects and shock,
on, colectomy or death.
urable prognostic factors
of another cause:
te count >15 000 cells/
g/L).
(133 mM/L or 1.5 times
Incorporated in definition of severe CDI
er:
lls/mm3.





 Significant abdominal distension.
 Alteration of mental status.
 White blood count 35 000 cells/mm3
or <2000 cells/mm3.
 Serum lactate level >2.2 mmol/L.
 End organ failure.
unt of 15 000 cells/mL or
s premorbid level
Hypotension or shock, ileus, megacolon
Fig. 1. PRISMA flowchart showing search of clinical trials.
Table 2
New treatments tested for CDI
Agent Manufacturer Type or class Clinical trial Registered Indication
Actoxumab Merck & Co. Antitoxin A (MK-3415) human monoclonal
antibody
Phase 3 terminated No rCDI
Bezlotoxumab Merck & Co. Antitoxin B (MK-6072) human monoclonal
antibody
Phase 3 completed Yes, FDA approved rCDI
Cadazolid Actelion Pharmaceuticals Hybrid antibiotic, consisting of fluoroquinolone
and oxazolidinone moieties
Phase 3 completeda No CDI/first rCDI
CRS3123/REP3123 Crestone Inc. Antibiotic/methionyl-tRNA synthetase inhibitor Phase 1 completed No CDI
LFF571 Novartis Pharmaceuticals Semisynthetic thiopeptide antibiotic, related to
elfamycins
Phase 2 completed No CDI/First rCDI
Ridinilazole (SMT19969) Merck & Co Antibiotic/pyridyl-bibenzimidazole Phase 2 active No CDI
Rifaximin Salix Pharmaceuticals Antibiotic/rifamycins Phase 3 completed Yesb rCDI
Surotomycin Cubist Pharmaceutics Antibiotic/lipopeptides Phase 3 completed No CDI
Tigecycline Pfizer Antibiotic/glycylcycline Phase 2 discontinued Yesc CDI/rCDI
Faecal Microbiota
Transplantation
Self-provided/stool banks Organic microbiota Phase 3 completed Yes rCDI
SERES-109 Seres Therapeuticals Organic microbiota Phase 3 active No rCDI
SERES-232 Seres Therapeuticals Synthetic microbiota Phase 1 active No CDI
VP20621 Shire Orally administered nontoxigenic Clostridium
difficile
Phase 2 completed no rCDI
Ribaxamase/SYN004 Synthetic Biologics Class A b-lactamase designed to protect gut
microbiota from action of systemically
administered b-lactam antibiotics
Phase 2 completed No CDI
CDI, Clostridium difficile infection; FDA, US Food and Drug Administration; rCDI, recurrent Clostridium difficile infection.
a Awaiting publication.
b Rifaximin is registered for use in hepatic encephalopathy.
c Tigecycline is registered for complicated skin infections.
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large multicentre randomized controlled trials (RCT) show that
metronidazole is inferior to vancomycin in the treatment of CDI
(nonsevere and severe combined, with severe CDI defined as white
blood cell count 20 001/mm3, ten or more bowel movements perday and severe abdominal pain) [10]. Clinical success occurred in
202 (73%) of 278 patients who were treated with metronidazole
compared to 210 (81%) of 259 patients treated with vancomycin (p
0.02) [10]. However, subgroup analysis per severity of CDI did not
yield statistically significant results. A 2017 meta-analysis by
Table 3
Current treatment guideline of CDI by ESCMID [5]
Episode Treatment Nonantibiotic treatment
First choice Second choice Third choice
First episode of
nonsevere CDI
Metronidazole orally 500 mg three
times a day for 10 days
Vancomycin orally 125 mg four
times a day for 10 daysa
Fidaxomicin orally 200 mg two
times a day for 10 daysa
For mild cases; stop inducing
antibiotic and observe clinical
response at 48 hours
Severe episode of CDI Vancomycin orally 125 mg four
times a day for 10 days
Fidaxomicin orally 200 mg two
times a day for 10 days






Metronidazole 500 mg three times
a day 10 day and oral vancomycin
500 mg four times a day for 10 days
In case of colon perforation or
severe systemic inflammation,
abdominal surgery is indicated
First recurrence of CDI Vancomycin orally 125 mg four
times a day for 10 daysa
Fidaxomicin orally 200 mg two
times a day for 10 daysa
Multiple recurrences
of CDI
Fidaxomicin orally 200 mg two
times a day for 10 daysa
Vancomycin orally 125 mg four
times a day for 10 days, followed by
vancomycin pulse strategy or taper
strategya
FMT added to antibiotic
treatment
CDI, Clostridium difficile infection; ESCMID, European Society of Clinical Microbiology and Infectious Diseases; FMT, faecal microbiota transplantation.
a Equally effective.
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compared to vancomycin in the treatment of CDI. Since the publi-
cation of the ESCMID guidance document inwhich fidaxomicinwas
reserved for patients with relapsing CDI, a published meta-analysis
and indirect treatment comparison suggested that fidaxomicinmay
be considered as first-line therapy for CDI [83]; these observations
may reflect the slow and poor intestinal concentration of metro-
nidazole in the lower gastrointestinal tract [12]. A recent study
encompassing seven hospitals in the UK reported on the use of
fidaxomicin as the first agent of choice in all forms of CDI, but it also
mentioned that justification for severe CDI was not well studied
[13]. Guery et al. [14] in 2017 showed that a tapered treatment
schedule with fidaxomicin (days 1e5, treatment with 200 mg two
times a day, followed by once daily on alternating days during days
7e25) is superior (p 0.03) in resulting in a sustained clinical cure
(30 days after end of treatment) in CDI. Sustained clinical cure was
experienced by 124 (70%) of 177 patients compared to 125 mg
vancomycin four times a day for 10 days in 106 (59%) of 179 pa-
tients. These observations may have further impact on the use of
fidaxomicin as the first agent of choice, especially for patients at
high risk of relapse.
New agents for treatment of CDI
An overview of the reviewed agents is shown in Table 2.
Monoclonal antibodies bezlotoxumab and actoxumab
Bezlotoxumab (MK-6072) is a recombinant human IgG1/kappa
isotype monoclonal antibody. In 2016 it was approved globally for
use as an adjunctive treatment in patients at risk for rCDI (including
old age and/or use of antibiotics other than anti-CDI treatment)
[15]. Bezlotoxumab binds to regions of the combined repetitive
oligopeptide domains of the toxin that partially overlap with pu-
tative receptor binding pockets. It blocks the action of C. difficile
toxin B and potentially averts the damage and inflammation that
can lead to the symptoms associated with CDI [16]. Actoxumab
(previously known as MK-3415) binds specifically to toxin A and
was developed in conjunction with bezlotoxumab (previously
known as MK-3415A) [17]. The combined administration of these
two fully human monoclonal antibodies is designated actoxumab
and bezlotoxumab (previously known as MK-3415A). The half-life
of bezlotoxumab is 19 days; the Cmax measured following a
10 mg/kg dose iv was 185 mg/mL [18]. Studies of bezlotoxumab
concentrations in stool are very limited and inconclusive, as arestudies describing the bezlotoxumab concentration required for
inactivation of toxin B in the gut lumen to prevent rCDI.
Clinical trials
After analysing the results of the phase 1 trials for bezlotoxumab
and actoxumab, a combined single dose of 10 mg/kg was recom-
mended for further studies [19,20]. In the phase 2 multicentre
double-blind RCT, rCDI occurred in seven (7%) of 101 patients
treated with combined therapy with bezlotoxumab and actoxumab
added to a standard treatment regimen of vancomycin or metro-
nidazole compared to 25 (25%) of 99 patients in the placebo group
(p <0.001). No difference in number of days to resolution of CDI or
severity of infection was observed [21]. Two phase 3 studies were
conducted, MODIFY 1 andMODIFY 2, the results of which were also
published as pooled data (Table 4) [17]. In the interim analysis of
MODIFY 1, the rate of rCDI was found to be significantly higher in
the actoxumab group than in the combined group. Moreover, a
higher rate of serious adverse events and deaths was found to have
occurred in the actoxumab group compared to the placebo group.
Enrollment in the actoxumab group was therefore stopped. Pooled
results of MODIFY 1 and 2 showed a statistically significant
decrease in the occurrence of rCDI. Bezlotoxumab monotherapy
was found to be equally effective as combined actoxumab and
bezlotoxumab therapy. Therefore, only bezlotoxumab is registered
for treatment of CDI [17]. Searching ClinicalTrials.gov yielded one
trial that is currently recruiting to investigate the efficacy of
bezlotoxumab in children (NCT03182907).
Safety
In phase 3 studies, eight patients in the bezlotoxumab group
experienced congestive heart failure, versus two in the placebo
group [17]. This difference was not statistically significant. How-
ever, caution in patients with cardiovascular disease, and conges-
tive heart failure in particular, should be warranted.
Antibiotics
Surotomycin
Surotomycin (CB-183,315; MK-4261) is an orally administered,
minimally absorbed semisynthetic narrow-spectrum cyclic pep-
tide. Surotomycin is formed by enzymatical cleavage of daptomycin
[24]. It disrupts the bacterial membrane by acting as a calcium-
Table 4
Phase 3 studies completed and published before 20 September 2017
Characteristic Wilcox et al. [17],
bezlotoxumab
Boix et al. [22], surotomycin Daley et al. [23], surotomycin Major et al., rifaximina
Study design RCT RCT RCT RCT
No. centres enrolled 322 115 104 23
No. treatment arms 4 2 2 2
No. participants (controls) 2559 (773) 570 (280) 577 (292) 151 (77)
Dose 10 mg/kg iv 250 mg two times a day 250 mg two times a day 400 mg three times a day,
200 mg three times a day
Treatment regiment Single dose 10 days 10 days 2 þ 2 weeks
Comparator Placebo Vancomycin 125 mg four times
a day
Vancomycin 125 mg four times
a day
Placebo
Inclusion criteriab Adults with primary or
recurrent CDI who received oral
standard-of-care antibiotics
(metronidazole, vancomycin or
fidaxomycin, chosen by treating
physician) for 10 to 14 days




Exclusion criteriab  Patient with planned surgery
for CDI within 24 hours
 Life expectancy <72 hours
 Toxic megacolon and/or
small bowel ileus
 More than two episodes of
CDI within 90 days of trial
therapy
 Toxic megacolon and/or
small bowel ileus
 More than 2 episodes of CDI
within 90 days of trial
therapy




assays, culture with toxin
detection or strain typing and
commercial assays that detect
(at least) toxin B or its gene
Enzyme immunoassay, PCR or
cell culture cytotoxin
neutralization assay
Enzyme immunoassay, PCR or
cell culture cytotoxin
neutralization assay









No No No Unknown
Primary end point rCDI within 12 weeks after
resolution of initial CDI
End of treatment cure rate,
noninferiority
End of treatment cure rate,
noninferiority
rCDI within 12 weeks after start
of treatment
Primary outcome
Investigational product 17% 79% 83% 16%
Comparator 27% 84% 82% 30%
Outcome p <0.001 Inferior to vancomycin Noninferior to vancomycin p 0.06
Initial cure rate
Investigational product 80% 79% 83% NA
Comparator 80% 84% 82% NA
Sustained curec
Investigational product 64% 60% 63% 84%
Comparator 54% 61% 59% 70%
CDI, Clostridium difficile infection; ESCMID, European Society of Clinical Microbiology and Infectious Diseases; NA, not applicable; rCDI, recurrent Clostridium difficile infection;
RCT, randomized controlled trial.
a Major G et al., “PWE-050 follow-on rifaximin for the prevention of recurrence in Clostridium difficile associated diarrhoea: a randomised controlled trial,” Gut 2017; 66:
abstract 150.
b Summary of most important criteria.
c Sustained cure is defined as rate (%) of participants without rCDI upon initial cure in follow-up period.
R.E. Ooijevaar et al. / Clinical Microbiology and Infection 24 (2018) 452e462456dependent cell membrane depolarizing agent [25]. Surotomycin
has a fourfold greater in vitro potency than vancomycin against
C. difficile and other Gram-positive bacteria, with minimal impact
on the Gram-negative organisms of the intestinal microbiota
[24,26]. The half-life time of surotomycin ranges between 14.8 and
21.1 hours [27]. The effect of surotomycin on the composition and
diversity of the gut microbiota is limited [28].
Clinical trials
A treatment dose of 125 or 250 mg surotomycin administered
two times a day was recommended as result of the phase 1 trials
[27]. The phase 2 trial that followed showed end-of-treatment cure
rates of 92% in the 125 mg surotomycin group, 87% in the 250 mg
surotomycin group and 89% in the vancomycin group [29]. The
recurrence rate was significantly lower in patients treated with
surotomycin. Two parallel phase 3 studies comparing surotomycin
to oral vancomycin (Table 4) were conducted [22,23]. The results
could not confirm the observations of the phase 2 study. Interest-
ingly, in subjects infected with the C. difficile BI/NAP1/027 strain at
baseline, the cure rate and sustained clinical response rate werenumerically higher, with lower recurrence rates in patients treated
with surotomycin versus vancomycin, although this was not sta-
tistically significant. These results stopped the development of
surotomycin in CDI treatment.
Rifaximin
Rifaximin is a minimally absorbable antibiotic [30]. Rifaximin is
related to the rifamycin class of antibiotics, but rifaximin possesses
an extra pyridoimidazole ring [31,32]. Rifaximin shows in vitro ac-
tivity against C. difficile [33], but high-level resistance to rifaximin
in C. difficile (associated with rpoB mutations) has been reported
[34]. The effects on the microbiota are not clear, though it does not
induce dramatic shifts in the microbiota composition [35,36].
Clinical trials
After primary therapy of CDI with either metronidazole or
vancomycin, in one phase 2 study, rifaximin was found to be
equally effective as placebo in avoiding relapse (relative risk, 0.61;
95% confidence interval 0.36e1.02). The quality of evidence was
R.E. Ooijevaar et al. / Clinical Microbiology and Infection 24 (2018) 452e462 457low as a result of a high risk of bias and imprecision [37]. In a phase
3 trial (available only as an abstract; Table 4), 16% of patients treated
with rifaximin experienced rCDI, versus 30% in the placebo group
(p 0.06) (Major G et al., “PWE-050 follow-on rifaximin for the
prevention of recurrence in Clostridium difficile associated diar-
rhoea: a randomised controlled trial,” Gut 2017; 66: abstract 150).
Recently a second randomized placebo controlled phase 3 trial has
been completed (RAPID study: rifaximin for preventing relapse of
Clostridium associated diarrhoea) which is awaiting data analysis
(National Institute for Health Research RfPB, PB-PG-1010-23257).
Cadazolid
Cadazolid is a bacterial protein synthesis inhibitor and is clas-
sified as an oxazolidinone antibiotic. Cadazolid also contains parts
of the chemical structure of the fluoroquinolone class of antibiotics
in the form of a quinolone nucleus [38]. The quinolone nucleus in
cadazolid causes only a weak DNA synthesis inhibition. A preclin-
ical study shows that cadazolid has bactericidal activity against
C. difficile [39]. Single and multiple (twice daily for 10 days) oral
doses of cadazolid up to 3000 mg administered two times a day to
healthy volunteers revealed that 81% to 86% of cadazolid was
measured unchanged in faecal samples, suggesting minimal sys-
temic absorption [39]. A study by Chilton et al. [40] shows that
cadazolid has little effect on the commensal gut microbiota.
Clinical trials
In the phase 2 study, a better cure rate was observed for patients
treated with cadazolid compared to vancomycin (Table 5). The
recurrence rate was only provided in a modified intention-to-treat
analysis: two (18%) of 11, three (25%) of 12 and two (22%) of nine in
the cadazolid groups versus seven (50%) of 14 in the vancomycin
group, respectively [41]. The sustained cure rate for all doses of
cadazolid was significantly higher than vancomycin, but the
observed cure rate in patients treated with vancomycin was lower
than reported elsewhere. Currently two phase 3 trials have been
completed: NCT01983683 and NCT01987895 (ClinicalTrials.gov),
the results of which will be available soon. One clinical trial
investigating the effect of cadazolid in children is recruiting pa-
tients (NCT03105479).
LFF571
LFF571 is a semisynthetic thiopeptide antimicrobial with potent
in vitro antibacterial activity against Gram-positive bacteria,
including C. difficile [42]. LFF571 targets the essential process of
translation through impairment of elongation factor-Tu function. It
is related to the family of elfamycins, a relatively understudied
group of antibiotics [43]. Serum and faecal levels of LFF571 have
been evaluated following a 200 mg four times a day dose for
10 days in patients with moderate CDI. High levels of LFF571
measured in faeces (median 3240 mg/mg) and low levels measured
in serum (maximum 41.7 ng/mL) suggest minimal systemic ab-
sorption [44].
Clinical trials
A phase 1 trial evaluated the safety of a single dose of LFF571 up
to a 1000 mg, as well as 200 mg four times a day for 10 days [45]. In
a phase 2 trial, patients treated with LFF571 had better initial cure
rates [46], but no significant difference was found in the occurrence
of rCDI cases confirmed with toxin testing (Table 5). It was
concluded that LFF571 was noninferior to vancomycin treatment
[46]. Currently no phase 3 trials are underway.Ridinilazole
Ridinilazole (formerly known as SMT19969) is a novel small-
spectrum, nonabsorbable antibiotic specifically developed for CDI
treatment. In vitro studies have shown its high inhibitory activity
against C. difficile and minimal activity against both Gram-positive
and Gram-negative aerobic and anaerobic intestinal microorgan-
isms [47]. The working mechanism of ridinilazole has not yet been
completely elucidated, but it is suggested that it may impair cell
division [48]. Nearly all ridinilazole is passed unchanged through
faeces. The effects on the gut microbiota were found to be minimal
[49].
Clinical trials
In a phase 2 study (Table 5), the primary end point was reso-
lution of CDI and no rCDI 30 days after the end of the trial [50]. The
end point was met in 32 (64%) of 50 participants in the ridinilazole
group versus 25 (50%) of 50 in the vancomycin group (p 0.002).
RCDI occurred in four (11%) of 36 participants in the ridinilazole
group versus 12 (32%) of 37 participants in the vancomycin group.
Further analyses were done in a modified intention-to-treat anal-
ysis (Table 5). One phase 2 trial (NCT02784002) comparing the
efficacy of ridinilazole versus fidaxomicin has just been completed
(Mitra S et al., “Preservation of gut microbiome following rid-
inilazole versus fidaxomicin treatment of Clostridium difficile
infection,” poster abstract presented at IDWeek, San Diego, CA, 7
October 2017).
Tigecycline
Tigecycline has an expanded broad-spectrum antibiotic activ-
ity and acts as a protein synthesis inhibitor [51]. Similar to tetra-
cycline antibiotics, tigecycline exerts bacteriostatic activity against
C. difficile [33]. Currently tigecycline is not registered for use in
CDI, but it is approved for complicated skin, soft tissue and
complicated intra-abdominal infections [52]. In CDI, a retrospec-
tive cohort study analysing 45 patients with severe CDI (severity
defined by clinical criteria) receiving tigecycline monotherapy and
45 patients receiving standard therapy alone revealed that pa-
tients treated with tigecycline had significantly better outcomes of
clinical cure, less complicated disease course and less CDI-
associated shock [53]. However, two retrospective cohort studies
failed to demonstrate a difference in outcome of patients receiving
adjunctive tigecycline and those who did not [54,55]. It is clear
that RCTs are needed to elucidate the role of tigecycline in the
management of severe CDI. One phase 2 trial was started but
discontinued because of slow enrollment. The results were never
published (NCT01401023).
CRS3123
CRS3123 has currently completed two phase 1 studies. CRS3123
inhibits bacterial methionyl-tRNA synthetase, thereby preventing
growth and toxin production in C. difficile. It has shown potent
activity against C. difficile (minimum inhibitory concentration
0.5e1 mg/mL), aerobic Gram-positive bacteria and Gram-negative
bacteria, including anaerobes [56]. In a first phase 1 study, plasma
concentrations of CRS3123 peaked after 2 to 3 hours and rapidly
declined after 12 hours. Further systemic and faecal exposure will
be investigated in future studies [57]. CRS3123 doses up to 1200mg
were found to be safe and well tolerated, with no serious adverse
events reported. The most common adverse events in the CRS3123
group were decreased haemoglobin (23%) and headache (20%) [57].
Phase 2 studies are expected to start in the near future.
Table 5
Phase 2 completed and no results of phase 3 available before 20 September 2017
Characteristic Louie et al. [41], cadazolid Mullane et al. [46], LFF571 Vickers et al. [50], ridinilazole Gerding et al. [78],
nontoxigenic Clostridium
difficile
No. centres enrolled 9 25 33 44
No. treatment arms 4 2 2 4
No. participants (controls) 84 (22) 72 (26) 100 (50) 173 (44)
Dose  250 mg 2 times a day
 500 mg 2 times a day
 1000 mg 2 times a day
200 mg four times a day 200 mg 2 times a day  104 spores per day
 107 spores per day
 107 spores per day
Treatment regimen 10 days 10 days 10 days 7 or 14 days
Comparator Vancomycin 125 mg four times
a day
Vancomycin 125 mg four times
a day
Vancomycin 125 mg four times
a day
Placebo
Inclusion criteriaa Adults with primary CDI or first
rCDI
Adults with mild to moderately
severe primary CDI or first rCDI
Adults with primary CDI Adults with primary or first
rCDI who clinically recovered
from a standard treatment
Exclusion criteriaa  Ileus
 Severe abdominal tenderness
 Toxic megacolon
Severe CDI Life-threatening or fulminant
CDI with evidence of
hypotension (systolic blood
pressure <90 mm Hg), septic
shock, peritoneal signs or ileus
or toxic megacolon
 rCDI
 Other treatments than
vancomycin or
metronidazole
 Presence of bowel disease or
previous (6 weeks) bowel
surgery
 Toxic megacolon





C. difficile toxin A/B assay and/or
PCR
C. difficile toxin A/B or B assay Toxigenic strain by nucleic acid
amplification tests or free toxin
by enzyme immunoassay





No No No Yes
Primary end point No additional CDI treatment
necessary after 10 days of
treatment, superiority
Clinical cure within 1e3 days
after end of treatment,
noninferiority
Resolution of CDI symptoms
and no rCDI within 30 days
after end of treatment,
noninferiority
Safety and tolerability of NTCD-
M3 within 7 days of treatment;
clinical: rCDI from day 1
through week 6
Primary outcome
Investigational product  250 mg: 77%
 500 mg: 80%
 1000 mg: 68%
91% 64% rCDI:
 104 spores 7 days: 15%:
 107 spores 7 days: 5%
 107 spores 14 days: 15%
Comparator 68% 78% 50% 30%
Outcome Not superior Noninferior Noninferior p 0.006
Initial cure rate
Investigational product
 250 mg: 77%
 500 mg: 80%




Comparator 68% 78% 70% NA
Sustained cureb MITT:
Investigational product  250 mg: 60%
 500 mg: 56%
 1000 mg: 47%
57% 67%  104 spores 7 days: 85%:
 107 spores 7 days: 95%
 107 spores 14 days: 85%
Comparator 33% 65% 42% 70%
CDI, Clostridium difficile infection; ESCMID, European Society of Clinical Microbiology and Infectious Diseases; MITT, modified intention-to-treat analysis; NA, not applicable;
rCDI, recurrent Clostridium difficile infection.
a Summary of most important criteria.
b Sustained cure is defined as rate (%) of participants without rCDI upon initial cure in follow-up period.
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Faecal microbiota transplantation
Recurrences of CDI are associated with an impaired immune
response to C. difficile toxins and/or alteration of the colonic
microbiota [58,59]. FMT restores the composition and functionality
of the gut microbiota, including restoration of colonization resis-
tance, recovery of the secondary bile acid synthesis and inhibiting
secondary bile acids direct suppression by antimicrobial peptides
and/or reintroduction of bacteriophages [60,61].
Donor faeces can be administered by nasogastric tube, duodenal
tube, colonoscopy, enema and capsules. Before FMT, patients are
treated with antibiotic therapy directed at CDI for at least 4 days.Additionally, 1 day before FMT, bowel lavage is performed in most
patients [62]. It has been suggested that at least 50 g of donor faeces
should be used for a single treatment with FMT [63].
Clinical trials
After the first RCT by van Nood et al. [64], many clinical trials
have been performed to study the efficacy and safety of FMT in the
treatment of rCDI [65e70]. In the study by Orenstein et al. [69], the
faecal microbiota product was provided by Rebiotix, a commercial
biotechnology company, whereas in the other trials noncommercial
products were used [64e70]. The reported cure rates vary between
44% and 94% (Table 6). A recent meta-analysis by Moayyedi et al.
[71] underlines the efficacy of FMT in the treatment of rCDI (pooled
risk ratio of 0.41 for the persistence of CDI). However, great
Table 6







Follow-up Antibiotic treatment before
FMT
Volume of donor faeces per
FMT
Resolution of rCDI
Van Nood et al. [64] 42 (16) Duodenal tube Yes 10 weeks 4e5 days vancomycin 500 mg
four times a day
Faeces diluted to 500 mL  1st FMT: 81%
 2nd FMT: 94%
Cammarota et al. [65] 39 (20) Colonoscopy Yes 10 weeks 3 days vancomycin 125 mg four
times a day
Faeces diluted to 500 mL  1st FMT: 65%
 2nd FMT: 80%
 3rd FMT:85%
 4th FMT: 90%
Kelly et al. [68] 46 (22) Colonoscopy Yes 8 weeks >10 days vancomycin 100 g faeces diluted to 500 mL  1st FMT: 91%
Orenstein et al. [69] 40 Enema No 8 weeks 7 days vancomycin 125 mg four
times a day
50 g faeces diluted to 150 mL  1st FMT: 52%
 2nd FMT: 87%
Hota et al. [66] 30 (16) Enema No 120 days 14 days vancomycin 125 mg
four times a day
50 g faeces diluted to 500 mL  1st FMT: 44%
Youngster et al. [70] 180 (180) Capsules No 8 weeks >1 day of vancomycin,
metronidazole or fidaxomicin
48 g faeces diluted into 30
capsules
 1st FMT: 82%
 2nd FMT: 91%
 3rd FMT: 93%
Kao et al. [67] 116 (57) Capsules Yes >8 weeks >10 days vancomycin 125 mg
four times a day
80e100 g faeces diluted into 40
capsules
 1st FMT: 96.2%
FMT, faecal microbiota transplantation; NTCD-M3, nontoxigenic Clostridium difficile strain M3; rCDI, recurrent Clostridium difficile infection.
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used donor faeces volume, route of administration, pretreatment
and number of FMTs.
Currently FMT is mainly used to prevent further recurrences in
rCDI and is performed after initial anti-CDI antibiotic therapy. A
recently published review, however, concluded that FMT with or
without additional antibiotic CDI treatment might also be a
promising curative treatment alternative in patients with severe
CDI or rCDI [90]. One currently active clinical trial (NCT02570477) is
studying the efficacy of FMT in severe CDI.
Safety
FMT is generally safe and well tolerated. The most commonly
noted adverse events are bloating, abdominal cramps, nausea,
diarrhoea or constipation [64e66,68e70]. Most serious adverse
events are procedure related according to the route of adminis-
tration, or according to colonoscopy or duodenal tube placement.
Aspiration during sedation for colonoscopy, septic shock with toxic
megacolon and aspiration pneumonia due to regurgitation of faecal
matter have been reported [72,73]. Less is known about the long-
term effects of FMT. The development of long-term effects,
including malignancies, autoimmune diseases and other gut
microbiotaeassociated diseases in patients who received FMT,
should be investigated in the future. A recent publication stimu-
lates the development of national centres that also provide long-
term follow-up data on patients treated with FMT [74]. These
centres should only administer FMT after appropriate approval
from the competent body. Unfortunately, the legal and regulatory
framework relating to FMT is highly variable between countries.
Other microbiome therapeutics
Several commercial organizations are providing faecal micro-
biota transplants as microbiome therapeutics. For the purpose of
this review, we only include products composed of cultured mi-
croorganisms from which data have been presented or published.
SERES-109 is composed of bacterial spores from healthy human
donors. It is designed to restore dysbiosis in the gut microbiota,
thereby preventing rCDI [75]. The first preliminary results were
presented of a placebo-controlled phase 2 trial of a single-dose SER-
109 to reduce rCDI up to 8 weeks after treatment (Trucksis M, “An
analysis of results from the first placebo-controlled trial of single-
dose SER-109, an investigational oral microbiome therapeutic to
reduce the recurrence of Clostridium difficile infection (CDI),” paper
presented at the 27th European Congress of Clinical Microbiologyand Infectious Diseases, Vienna, Austria, 2017). However, the pri-
mary end point did not show a statistically significant difference
between SER-109 and placebo arms regarding recurrence rates
(44.1% vs. 53.3% recurrence, respectively). It was concluded that a
dose increase may be necessary and that diagnostic accuracy
needed improvement by direct toxin testing instead of PCR anal-
ysis, as recommended by 2016 ESCMID CDI guidelines [76]. SERES-
262 is a new synthetically derived microbiome therapeutic and
therefore does not require human donor material. At present, a
phase 1 study is evaluating the safety and efficacy of SERES-262 for
the prevention of rCDI in patients with primary CDI ([http://www.
serestherapeutics.com/clinical-trials/overview] 2017).
Nontoxigenic Clostridium difficile strains
Nontoxigenic C. difficile (NTCD) strains lack the genes for toxin
production. NTCD strains are capable of colonizing patients and
preventing CDI by a toxigenic strain [77]. One of these NTCD strains,
M3 (VP20621; NTCD-M3), has shown to safely colonize healthy
volunteers [77]. In a completed phase 2 study (Table 5), treated
participants experienced resolution of CDI after metronidazole or
vancomycin treatment with differing doses of NTCD-M3 spores
[78]. The treatment was well tolerated and appeared to be safe.
NTCD-M3 colonized the gastrointestinal tract and significantly
reduced CDI recurrence, though the highest dosage prescribed for
14 days was less effective than a similar dosage for 7 days, and not
all treated individuals became colonized. This difference was
associated with less colonization of NTCD-M3 in the 14-day treat-
ment group. A phase 3 trial is currently not underway.
Antibiotic inactivator to prevent CDI development
Ribaxamase
Ribaxamase (SYN-004) is a b-lactam cleaving enzyme. It is
engineered as a pH-dependent formulation and is released in the
proximal small intestine [79]. Ribaxamase is designed for oral
administration concomitantly with iv b-lactam antibiotics to pre-
vent their disruption of gut microbiota [80]. Ribaxamase acts via
enzymatic degradation of excess b-lactam antibiotics that are
excreted in the small intestine, thus preventing alterations of the
gut microbiota. A phase 1 study showed no adverse events in
healthy volunteers [81]. A recent phase 2a study shows proof of
concept in humans [82]. A phase 2b study is currently underway,
but preliminary results have been presented (Kokai-Kun JF, “SYN-
R.E. Ooijevaar et al. / Clinical Microbiology and Infection 24 (2018) 452e462460004 (ribaxamase) significantly reduced the incidence of Clostridium
difficile infection in a phase 2b clinical study,” paper presented at
the 27th European Congress of Clinical Microbiology and Infectious
Diseases, Vienna, Austria, 2017). Released top-line data show a
relative risk reduction of 71% for CDI and 41% for colonization with
multidrug-resistant organisms. Ribaxamase also significantly
reduced dysbiosis in the gut microbiota. Ribaxamase did not affect
the efficacy of iv ceftriaxone treatment.
Conclusions
The cornerstones of CDI treatment, metronidazole and vanco-
mycin, are associated with a 20% risk of rCDI after primary infec-
tion. Metronidazole is mentioned in the ESCMID guideline as first-
line therapy, but it appears less effective than vancomycin in
inducing initial cure, especially for severe clinical forms of CDI
[10,11,91]. Compared to vancomycin, fidaxomicin results in a similar
initial cure rate in patients with a first episode of CDI but a signif-
icant reduction of rCDI [13,14,83]. Nonetheless, treatments with an
even higher sustained cure rate are needed. In recent years, mul-
tiple novel treatment modalities for (r)CDI have been investigated.
Although some show promising results, limitations of the
studies with new agents should be addressed. Firstly, most of the
studies were active comparator studies comparing vancomycin
with other antibiotics. This makes it difficult to assess performance
compared to fidaxomicin or FMT. Secondly, only a few studies
follow the ESCMID recommendations to use a two-step algorithm
with a toxin detection test as an important tool to determine the
activity of CDI [76]. Inappropriate testing algorithm may result in
treatment of C. difficile carriers instead of CDI [84,85]. The third
limitation is the lack of a standardized definition for a rCDI. Pref-
erably, both clinical criteria (e.g. more than 2 days of at least three
loose stools per day) and microbiologic criteria (positive toxin test
and exclusion of other enteropathogens) should be used. The large
variation of reported recurrence rates indicate that standardization
is urgently needed. Lastly, we did not include cost-effectiveness
studies, as costs are highly variable between countries and in-
stitutions, and costs are often biased by industry and greatly
depend on the chosen effectiveness [86].
No firm recommendations can be given for the efficacy of
antibiotic treatment in severe CDI, as most studies excluded pa-
tients with severe disease, following the ESCMID definition [5].
Severity of CDI has been measured using many different methods,
sometimes specifically defined for a treatment study [87]. The
definition varies between different guidance documents, as sum-
marized in Table 1. It should be emphasized that none of the
definitions has been validated. In patients with mild CDI, the lack
of ‘no treatment’ control studies does not allow for any conclusions
to be drawn regarding the need for treatment beyond withdrawal
of the initiating antibiotic. We still consider this a first approach
for the treatment of the individual patient with mild CDI. We
propose that oral vancomycin becomes the first choice when
antibiotic treatment for nonsevere CDI is necessary due to a higher
efficacy in inducing initial cure [10,11,87]. Fidaxomicin is a good
alternative for vancomycin in patients at risk for development of
rCDI, such as elderly patients, those with severe comorbidity and
those with low serum antibodies to C. difficile toxins [13,14,83].
Bezlotoxumab is an interesting new therapeutic approach using a
humanmonoclonal antibody against C. difficile toxin B. The studied
patients seem to have mainly experienced mild to moderate CDI,
thus causing us to question the applicability or generalizability of
the study results to patients with more severe CDI [17]. Further-
more, the clinical relevance of the difference of 12% to 13%
reduction in rCDI by fidaxomicin and 10% by bezlotoxumab must
be questioned.It is expected that new products that influence the serum
antibody response or the human microbiota composition will be
further developed. Though vaccination trials are currently being
performed, a recent phase 3 trial (using inactivated C. difficile toxins
A and B) has been preliminary ended by Sanofi SA after analysis by
an independent data monitoring committee. To date, FMT remains
the primary therapy for multiple rCDI. Faecal microbiota products
do not differ greatly in terms of efficacy [88], but standardized
mixtures of bacteria to replace FMT have not proven successful so
far. The encapsulation of donor faeces may further simplify the
treatment of patients with FMT in the future [67,70]. We also
anticipate that new medication that protects the microbiota, such
as ribaxamase or DAV132 (an adsorbent for antibiotic residue in the
colon), will be further developed and tested to prevent CDI devel-
opment during antibiotic therapy (Kokai-Kun JF, “SYN-004 (ribax-
amase) significantly reduced the incidence of Clostridium difficile
infection in a phase 2b clinical study,” paper presented at the 27th
European Congress of Clinical Microbiology and Infectious Diseases,
Vienna, Austria, 2017) [82,89].
In conclusion, recent progress in the treatment of CDI is modest,
although promising agents are being tested. Interestingly, nonan-
tibiotic treatment strategiesdsuch as microbiota targeting ap-
proaches, microbiota preserving preventive strategies and toxin
targeting antibodiesdmay change the battlefield in the fight
against CDI.
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